Latest News
Biogen Releases Q2 Community Statement on Latest Milestones in Clinical Development Program
Dear Members of the SMA Community, In light of the COVID-19 pandemic and the burden it has placed on our healthcare system, Biogen is working with health systems, institutions, physicians, […]
Read More ›Update from Scholar Rock on TOPAZ Phase 2 Clinical Trial of SRK-015 in Patients with SMA
Scholar Rock recently reported financial results for the first quarter ending March 31, 2020, highlighting progress and upcoming milestones for its pipeline programs—include the SRK-015 program for spinal muscular atrophy […]
Read More ›Genentech’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 SMA
Genentech, a member of the Roche Group, today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1-7 months old with symptomatic […]
Read More ›Annual Cure SMA Community Update Survey Ready for Your Input
Navigating the recent global health crisis, Coronavirus (COVID-19), has reinforced for us the importance of understanding what the SMA community is thinking, feeling, and experiencing. This allows us to more […]
Read More ›Cure SMA Launches New COVID-19 Support Package
Despite the new reality of quarantines, remote working, and social distancing, Cure SMA would like you to know that our work for the SMA community continues. Cure SMA remains vigilant […]
Read More ›COVID-19 Assistance Program Available to SMA Community
Cure SMA realizes that quarantining is essential for individuals and families who live with SMA, many of whom are experiencing hardships due to the COVID-19 pandemic. In response, we are […]
Read More ›